{Reference Type}: Journal Article
{Title}: Dexmedetomidine mitigates acute kidney injury after coronary artery bypass grafting: a prospective clinical trial.
{Author}: Zhang C;Zhang Y;Liu D;Mei M;Song N;Zhuang Q;Jiang Y;Guo Y;Liu G;Li X;Ren L;
{Journal}: Rev Esp Cardiol (Engl Ed)
{Volume}: 0
{Issue}: 0
{Year}: 2024 Feb 27
暂无{DOI}: 10.1016/j.rec.2024.02.005
{Abstract}: <B>OBJECTIVE: </B>To evaluate the impact of dexmedetomidine impact on cardiac surgery-associated acute kidney injury (CSA-AKI), kidney function, and metabolic and oxidative stress in patients undergoing coronary artery bypass grafting with heart-lung machine support.<BR><B>METHODS: </B>A randomized double-masked trial with 238 participants (50-75 years) undergoing coronary artery bypass grafting was conducted from January 2021 to December 2022. The participants were divided into Dex (n=119) and NS (n = 119) groups. Dex was administered at 0.5 mcg/kg over 10minutes, then 0.4 mcg/kg/h until the end of surgery; the NS group received equivalent saline. Blood and urine were sampled at various time points pre- and postsurgery. The primary outcome measure was the incidence of CSA-AKI, defined as the occurrence of AKI within 96hours after surgery.<BR><B>RESULTS: </B>The incidence of CSA-AKI was significantly lower in the Dex group than in the NS group (18.26% vs 32.46%; P=.014). Substantial increases were found in estimated glomerular filtration rate value at T4-T6 (P<.05) and urine volume 24hours after surgery (P<.01). Marked decreases were found in serum creatinine level, blood glucose level at T1-T2 (P<.01), blood urea nitrogen level at T3-T6 (P<.01), free fatty acid level at T2-T3 (P<.01), and lactate level at T3-T4 (P<.01).<BR><B>CONCLUSIONS: </B>Dex reduces CSA-AKI, potentially by regulating metabolic disorders and reducing oxidative stress.